The European Medicines Agency’s main scientific committee has given a positive opinion to a new drug developed by GlaxoSmithKline Plc for people with Type 2 diabetes. The drug, albiglutide, is a glucagon-like peptide-1 receptor agonist. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
